What is the prevalence of malignancy in deep venous thrombosis (DVT)?

Updated: Jun 05, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print

Malignancy is noted in as many as 30% of patients with venous thrombosis. [73, 77] The thrombogenic mechanisms involve abnormal coagulation, as evidenced by 90% of cancer patients having some abnormal coagulation factors. [78] Chemotherapy may increase the risk of venous thrombosis by affecting the vascular endothelium, coagulation cascades, and tumor cell lysis. The incidence has been shown to increase in those patients undergoing longer courses of therapy for breast cancer, from 4.9% for 12 weeks of treatment to 8.8% for 36 weeks. [79] Additionally, DVT complicates 29% of surgical procedures done for malignancy. [80]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!